Financing ·
DNA X, Inc. issued 929,864 shares of Series B Preferred Stock on July 8, 2026, generating $2.5 million in cash…
SONMDNA X, Inc.
DNA X, Inc. issued 929,864 shares of Series B Preferred Stock on July 8, 2026, generating $2.5 million in cash proceeds and facilitating the cancellation of a $3.1 million convertible promissory note balance. The company expects to issue the remaining 416,667 shares under the Purchase Agreement by August 14, 2026. Following these transactions, the company's pro forma stockholders' equity is estimated at $3.798 million, which exceeds the $2.5 million minimum requirement for continued listing on the Nasdaq Capital Market. DNA X, Inc. is a technology company.